The discovery that cancer cells overexpress the chemokine receptor CXCR4 and that its blocking can inhibit metastasis to organs that express its ligand, the chemokine CXCL12 [7,8,9], opened new therapeutic avenues for the targeting of metastatic breast cancer. Here, CXCR4 is linked to breast cancer.